Abstract.
Ribavirin, a broad spectrum antiviral agent, in conjunction with interferon forms the current standard of treatment for hepatitis C virus (HCV) infection in humans. While ribavirin alone fails to induce a significant antiviral response, in combination with interferon, ribavirin dramatically improves the long-term outcome of therapy. The predominant mechanism(s) of ribavirin action against HCV, are yet to be established. In this review, we examine the current status of our understanding of the metabolism, pharmacokinetics and mechanisms of the antiviral activity of ribavirin against HCV, all of which are central to the rational identification of improved treatment protocols.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 30 September 2005; received after revision 20 November 2005; accepted 7 December 2005
Rights and permissions
About this article
Cite this article
Dixit, N.M., Perelson, A.S. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell. Mol. Life Sci. 63, 832–842 (2006). https://doi.org/10.1007/s00018-005-5455-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-005-5455-y